Thymosin beta-4 and ILK/Akt: heart tissue research in mice
Evidence level: Cell and animal research: full-length thymosin beta-4 · Publication year: 2004
This overview discusses one original scientific publication on the context of Thymosin beta-4 / TB-500. The source is listed in PubMed, the literature database of the U.S. National Library of Medicine.
What was studied?
Researchers studied full-length thymosin beta-4 in relation to cell migration and survival. They also examined heart tissue after experimental occlusion of a coronary artery in mice.
What did the researchers find?
The publication reported activation of ILK/Akt, improved early survival of heart muscle cells, and improved measures of cardiac function in the mouse model.
What are the limitations?
Full-length thymosin beta-4 must not automatically be equated with every product called TB-500. Results in mice do not prove clinical benefit or safety in humans.
Significance for research
The connection with the TB-500 range is solely a literature context: peptide identity, sequence, and formulation must be established separately.
Official source
Original publication via PubMed — PMID 15565145 · DOI: 10.1038/nature03000
Research Use Only. This literature summary does not contain treatment or usage advice. Research on a molecule is not evidence of the efficacy, safety, or purity of a Peptidera product. PubMed indexing is not product approval.
Related research products
View product specifications and available batch documentation. The studies discussed were not conducted with Peptidera products and do not prove the efficacy of our products. For laboratory research only; not for human or animal consumption.